1. Liu, S., Wei, L. X., Yu, Q., Guo, Z. W., Zhan, C. Y., Chen, L. L*., ... & Ye, D*. (2025). Targeting IRG1 in tumor-associated macrophages for cancer therapy. Protein & Cell, 16(6), 478-483.

2. Chen, Y. J., Li, G. N., Li, X. J., Wei, L. X., Fu, M. J., Cheng, Z. L., ... & Chen, L. L*. (2023). Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy. Science advances, 9(17), eadg0654.

3. Chen, L. L., Morcelle, C., Cheng, Z. L., Chen, X., Xu, Y., Gao, Y., ... & Ye, D. (2022). Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses. Nature cell biology, 24(3), 353-363.

4. Chen, L. L., Smith, M. D., Lv, L., Nakagawa, T., Li, Z., Sun, S. C., ... & Xu, Y. P. (2020). USP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2. Science advances, 6(38), eabc9730.

5. Chen, L. L., Lin, H. P., Zhou, W. J., He, C. X., Zhang, Z. Y., Cheng, Z. L., ... & Guan, K. L. (2018). SNIP1 recruits TET2 to regulate c-MYC target genes and cellular DNA damage response. Cell reports, 25(6), 1485-1500.

6. Chen, L. L., & Xiong, Y. (2020). Tumour metabolites hinder DNA repair. Nature (News & Views)

7. Wang, P., Chen, L. L., Xiong, Y., & Ye, D. (2024). Metabolite regulation of epigenetics in cancer. Cell reports, 43(10).

 申请专利

(1) 熊跃，叶丹，陈磊蕾; 以衣康酸为起点抑制Tet靶点蛋白的药物开发, 2022-01-19, 中国, 201310647579.6 (专利，公开中)

(2) 熊跃，叶丹，陈磊蕾; CANCER THERAPY BASED ON TARGETING IRG1, 2023-04-28, PCT/CN2022/132360 (专利申请)

(3) 叶丹，陈磊蕾，魏林星; 靶向肿瘤相关巨噬细胞 IRG1 的小干扰RNA 及其用途, 202410261627.6, 中国 (专利申请)